MD, PhD - Scientific leader, clinical research manager and team leader - CHUGA
Dr Thomas DECAENS is Professor of Medecine at the University Grenoble-Alpes. He focuses on teaching and research in hepatocellular carcinoma with focus in liver transplantation and targeted therapy. Dr Decaens is member of the Institute for Advance Biosciences (IAB) (INSERM U1209) in the group of Pr P. Hainaut. Dr Decaens earned his medical degree in Hepatology and Gastroenterology in 2006 and his complementary medical degree in Medical Oncology in 2008. In addition, he is graduated in Molecular basis of oncogenesis from the University of Paris and he earned a Thesis in molecular Carcinogenesis from the University of Paris in 2007. He got a post-doc position at the National Institute of Health (Bethesda, USA) from 2011 to 2013 in the lab of Pr. S. Thorgeirsson.
He is head of the Department of clinical research and innovation of CHU Grenoble Alpes (strategic committee, management of research structures including 240 people, coordination of HR, financial direction), head of Hepato-gastroenterology and digestive oncology department (16 seniors MDs, 15 secretaries, 3 nurses coordinators, 6 medical units, and 120 paramedic employes) and head of the clinical research unit of the department of hepato-gastroenterology with more than 70 ongoing trials. Dr Decaens is coordinator of a large nationwide prospective study focuses on the identification of new predictive factors of HCC recurrence after liver transplantation and is implicated in numerous clinical trials of targeted therapy of HCC.
He lead a team devotes on liver cancer analysis at IAB, with special focus on immunomonitoring of patients treated for advanced HCC and on pre-clinical studies of new drugs based on an animal model of HCC in rats.
Dr Decaens is vice director of the French liver tumor network, member of the scientific college of the “Fédération Française de Cancérologie Digestive (FFCD)”, member of the national digestive oncology recommendations. He is advisor for several public and private companies, considered as KOL in liver cancer.